Comparative Pharmacology
Head-to-head clinical analysis: IMPOYZ versus LEGUBETI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IMPOYZ versus LEGUBETI.
IMPOYZ vs LEGUBETI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
IMPOYZ is a monoclonal antibody that binds to and inhibits the activity of interleukin-23 (IL-23), a cytokine involved in inflammatory and immune responses. By blocking IL-23, it reduces the production of pro-inflammatory cytokines and attenuates the inflammatory cascade.
Legubeti is a selective inhibitor of sodium-glucose cotransporter 2 (SGLT2), reducing renal glucose reabsorption and lowering blood glucose levels independently of insulin secretion.
100 mg orally twice daily
500 mg orally twice daily
None Documented
None Documented
Terminal elimination half-life 6–8 hours in adults with normal renal function; prolonged to 15–30 hours in severe renal impairment (CrCl <30 mL/min).
Terminal half-life: 12 hours; steady-state reached after 2-3 days; adjust dose in renal impairment
Primarily renal (70–80% as unchanged drug via glomerular filtration and tubular secretion); biliary/fecal (15–20%) with minor hepatic metabolism.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Category C
Category C
Unknown
Unknown